Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: taniguchi h, taniguchi y. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Inoue T, Okishio K, Nishino K, Kumagai T, Suzuki H, Hirashima T, Imamura F, Atagi S. Tamiya A, et al. Among authors: taniguchi y. Anticancer Res. 2017 Sep;37(9):5199-5205. doi: 10.21873/anticanres.11943. Anticancer Res. 2017. PMID: 28870955
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T. Shiroyama T, et al. Among authors: taniguchi y. Cancer Med. 2018 Jan;7(1):13-20. doi: 10.1002/cam4.1234. Epub 2017 Nov 18. Cancer Med. 2018. PMID: 29150906 Free PMC article.
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Suzuki H, Hirashima T, Atagi S, Imamura F. Tamiya M, et al. Among authors: taniguchi y. PLoS One. 2018 Feb 22;13(2):e0192227. doi: 10.1371/journal.pone.0192227. eCollection 2018. PLoS One. 2018. PMID: 29470536 Free PMC article.
2,415 results